spacer
home > > summer 2009 > big pharma: adapting and reacting
PUBLICATIONS


Big Pharma: Adapting and Reacting

There has been much commotion and disruption in the pharmaceutical industry in recent years, and there seems to be no sign of it letting up. As the pending patent cliff looms ever larger, companies are being forced to make some extremely painful decisions.

In the media, it seems as if not even a day goes by in which there isnít an announcement about another company announcing a new round of layoffs. There have been over 100,000 jobs lost in the pharmaceutical industry since 2003, with more planned for the coming year.

Layoffs represent one, albeit major, attempt to reduce costs. In many instances, the job losses are a result of a non-core skill that is being outsourced to a third party at a lower cost, or for a shorter period of time. However, there is only so much cost-cutting that can be done before companies start diminishing their infrastructure. In speaking with many industry participants, there is strong focus on the undercurrent of risk management in the industry, which has a far greater long-term impact than cost cutting. This focus on risk is pervasive throughout the industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Steiner is RegentAtlanticís Pharmaceutical Executive Services Group Leader. Michael currently advises many current and former executives and senior researchers of pharmaceutical and biotechnology companies. He has been recognised by Reuters AdvicePoint as a Top Adviser for 2008, with Top Rankings in several categories including the NJNY- PA region, advisers with a corporate executive focus and advisers under 40.
spacer
Michael Steiner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement